Journal article
Trends of Use and Outcomes Associated With Glycoprotein-IIb/IIIa Inhibitors in Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention
Rochelle M Gellatly, Cia Connell, Christianne Tan, Nick Andrianopoulos, Andrew E Ajani, David J Clark, Shane Nanayakkara, Martin Sebastian, Angela Brennan, Melanie Freeman, Jessica O'Brien, Laura A Selkrig, Christopher M Reid, Stephen J Duffy
ANNALS OF PHARMACOTHERAPY | SAGE PUBLICATIONS INC | Published : 2020
Abstract
Background: Glycoprotein IIb/IIIa inhibitors (GPIs) are a treatment option in the management of acute coronary syndromes (ACSs). Evidence supporting the use of GPIs predates trials establishing the benefits of P2Y12 inhibitors, routine early invasive therapy, and thrombectomy devices in patients with ACS. Objective: The aim of this study was to determine trends in GPI use and their associated outcomes in contemporary practice. Methods: We assessed GPI use in patients with ACS undergoing percutaneous coronary intervention (PCI) from the Melbourne Interventional Group registry (2005-2013). The primary endpoint was the 30-day incidence of major adverse cardiovascular events (MACE). The safety e..
View full abstractGrants
Funding Acknowledgements
Professor Duffy's and Professor Reid's work are funded by National Health and Medical Research Council of Australia Grants.